{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021981","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.946513+00:00","generated_at":"2026-06-04T22:04:54.419582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024","bullets":["Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).","Cash, equivalents & investments $65.6M as of Dec 31, 2023; runway into Q2 2025.","R&D expenses Q4 $6.4M (up from $5.0M YoY); full-year $25.0M (up from $16.8M).","Preliminary ADVANCED-1EXP TARA-002 data in NMIBC CIS expected 1H 2024; ADVANCED-2 data in 2H 2024.","Dosing underway in STARBORN-1 Phase 2 trial of TARA-002 for lymphatic malformations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021981","json":"https://secwatch.observer/filing/0001213900-24-021981.json","markdown":"https://secwatch.observer/filing/0001213900-24-021981.md","text":"https://secwatch.observer/filing/0001213900-24-021981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/ea0201584-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:04:54.419582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b923bb5998542112d2c4e57df1f82e72f54c807","claim":"Protara Therapeutics, Inc. reported the full year and fourth quarter ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share, EPS $3.57 per share.","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year and fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share"},{"label":"EPS","value":"$3.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}